New derivatives are designed as target directed MAO-B Inhibitors for medical care of the patients for neurodegenerative disorder. Molecular design and estimated pharmacokinetic properties have been evaluated by using Inventus v 1.1 software. The binding mode of the proposed compounds with target protein i.e. 1S2Q was evaluated and the resulting data from docking studies explained that newly designed derivatives have high and better affinity towards target protein. Based on these properties, the binding affinities are used for speeding up drug discovery process by eliminating less potent compounds from synthesis.
INTRODUCTION
Computer aided drug design (CADD) is the process which facilitates computational approaches and resources that are used in Design and Discovery of new therapeutic agents. 1 The discovery and development of new drugs are long, tedious, complex and costly process. 2 It is a typical drug discovery cycle, which takes 10-15 years and million dollar currency to introduce in marketplace. That's why CADD has been widely used in Pharmaceutical field to accelerate the designing process in most efficient way. 
MAO-B Inhibitor as therapeutic target
Parkinson's disease is a neurodegenerative disorder of the brain resulting in Dopamine deficiency caused by the progressive death of dopaminergic neurons. Selegiline is first class drug which inhibits Dopamine metabolism but its therapeutic effects are compromised by its neurotoxic metabolites. To overcome this obstacle, a novel MAO-B inhibitor Rasagiline was developed. It is biotransfered to aminoindan, a non-amphetamine compound. It is effective as monotherapy or adjunct to L-dopa for patients with Parkinson's patients. 4 
MATERIAL AND METHODS
Computing is used in various ways in drug discovery. Important example includes QSAR and Structure Based methods. Here we focused on Structure based methods.
These methods show increasing utility for the discovery of the lead compounds and for refinement of lead compounds and for re-engineering of drug to overcome certain types of resistance. It becomes important in the rapid growth in structural data and determined as part of a focused drug-discovery effort with a wellcharacterized target. 5 Here, Structure based Drug design approaches were employed to develop potent MAO-B inhibitors for the Parkinson drug candidate.
Overview of the Process
Methods used to design inhibitors ranged from graphical visualization of the ligand in the binding site cavity to calculation of relative binding affinities using molecular mechanics. It is important to understand the interaction of the ligand with its receptor protein by examining the 3-D structure of the protein target in complex with the ligand. It helps in studying the interaction with the Steps involved in structure based drug design
Target Protein Selection
The processes of structure based drug design often proceed through multiple cycles. The first cycle includes cloning, purification and structure determination of the target protein by one of three principle methods:-
(1) X-ray crystallography (2) NMR (3) Homology Modeling
The ideal target macromolecule for Structure based drug design is one that is closely linked to human disease and binds a small molecule in order to carry out a function.
RCSB-PDB (Research Collaboratory for Structural
Bioinformatics-Protein Data Bank) is the most common source of crystal structure and structural information for drug design. The crystal structure of MAO-B in complex with Rasagiline was selected for this study and obtained from RCSB-PDB with PDB ID-1S2Q. It has total 2 Chains, Resolution-2.07Å. The structure is shown in figure. Using the structural information obtained through PDB, the 3-D structure of target was then prepared for drug design program. 
Energy Minimization
In silico processing of protein structure starts with energy minimization, this tool uses steepest descent (SD) and Conjugate gradient (CG) algorithm to minimize the potential energy of protein molecule. 
Figure 2: Snapshot of Energy Minimization

Binding Pocket Detection
In Inventus v1.1 software, the active site detection in a protein structure is based on its geometry like volume, depth. We identified maximum 10 active sites with ranking order and selected the best active site. We also compared the active site residues of Reference Ligand and found that each of the residues of active site lies in Cavity 2. So Cavity 2 is considered as active site or binding pocket. 
High Throughput Screening
Virtual screening process needs the speed and accuracy, where speed is the time required in screening and accuracy is finding true positives from the screened compound pool of library.
It is based on the protocol developed to remove the false positive from the screened molecules. Molecule can be screened using customized library as well as embedded library.
Figure 5: List of Screened compounds by Hits-Gen
Molecular Docking
It starts with the knowledge of active sites or with the information about the ligand receptor complex. It predicts the non-covalent binding of macromolecule (receptor) and a small molecule (ligand). The key characteristic of good docking program is its ability to reproduce experimental binding poses of ligand.
Docking of small molecules to receptor structures has become increasingly important in the context of drug discovery. [7] [8] [9] Over the past few years a number of methods have been developed for performing (relatively) fast predictions for a series of molecules regarding their ability to bind to a protein binding site. 10 Analogue design is usually defined as the modification of a drug molecule in order to prepare a new molecule showing chemical and biological similarity with the original model compound. In this study Rasagiline was selected as reference molecule and its structure was obtained from PubChem. In the first step, the reference molecule was docked into the active site and its binding affinity was noted i.e. (-13.54 kcal/mol). The reference molecule was modified to develop more potent molecules/compounds based on the data of high throughput screening and SAR information.
Pose prediction versus affinity prediction
Technically, the placement of the molecules in the region of interest (e.g. the receptor-binding site) is referred to as 'docking', whereas the prediction of affinity is referred to as 'scoring'. The distinction between docking and scoring defines also the two major technical challenges faced by docking programs: to predict the binding mode of a molecule correctly (herewith also referred to as 'pose prediction', where 'pose' refers to the orientation and conformation of a molecule at the receptor binding site) 11 and to predict the binding affinity of compounds (or to produce a relative rank-ordering for a number of compounds) in a reliable manner. 12 In this study, prepared protein and all analogues were subjected to docking using Novo-Docker module of Inventus v1.1 software to carry out the protein analogue interaction studies.
RESULT AND DISCUSSION
By using Structure based drug design, we have designed 15 analogues. Docking was performed for analysis of protein ligand interactions using Inventus v1.1 software and results are shown in table 1.
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[244] CODEN (USA): JDDTAO After molecular docking, we have analyzed the ADME (structure only) properties of the all designed analogues by using pharmopredicta module of inventus. The key features of this module, which were used in our study, are described below: ADME (Structure Based)
1) Human Absorption, FDp (%) binned
Results are classified as
• Low (0-33% absorbed)
• Medium (33-64% absorbed)
• High (67-100% absorbed)
2) Caco-2 Permeability (A→ B or apical to basolateral)
Peff at pH 7.4 (cm/s) Additional output data provided by pkEXPRESS plus module only: Binding interactions of the designed leads are described as follows: The results shows that before synthesis, biological activity testing and clinical trials of new analogues, these drug designing methods are used for speeding up drug discovery process by eliminating less potent compounds from synthesis. It may have chances to show the better results than rasagiline in laboratory as well, therefore it could be used for future design, optimization and investigation to produce more effective analogues.
